Moleculin Biotech
MBRX
10 hedge funds and large institutions have $1.56M invested in Moleculin Biotech in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less capital invested
Capital invested by funds: $1.95M → $1.56M (-$385K)
23% less funds holding
Funds holding: 13 → 10 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$206K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$31.7K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$26.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.28K |
| 5 |
Morgan Stanley
New York
|
+$5.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$144K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$26.4K |
| 4 |
Jane Street
New York
|
-$22K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$19K |
MBRX Hedge Fund Activity: Q3 2017 in Review
10 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2017, worth a combined $1.56M — down 20% from $1.95M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MBRX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $206K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $144K sold.
- 10 institutional investors held Moleculin Biotech (MBRX) as of Q3 2017, down from 13 in Q2 2017.
- Funds reported $1.56M of Moleculin Biotech stock for Q3 2017, down 20% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q3 2017 and 5 closed out, a net change of -2 holders.
- The largest Moleculin Biotech buyer in Q3 2017 was Vanguard Group, an estimated $206K added.
- The largest Moleculin Biotech seller in Q3 2017 was Two Sigma Securities, an estimated $144K sold.
Based on aggregated 13F filings for Q3 2017.